Search Results

Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Radiopharmaceutical Development for Solid Tumors

Akiram Therapeutics, a Swedish clinical-stage biotechnology company, and ITM Isotope Technologies Munich SE, a German radiopharmaceutical biotechnology company, recently announced the signing of a supply agreement. Under the agreement, ITM will supply no-carrier-added lutetium-177 (nca Lu-177) to Akiram to support the clinical development of its targeted antibody-radionuclide conjugate, 177Lu-AKIR001 (AKIR001). AKIR001 is Akiram's lead radiopharmaceutical candidate, currently being investigated in clinical studies for the treatment of CD44v6-expressing solid tumors. The candidate combines the therapeutic radioisotope nca Lu-177 with a proprietary antibody targeting CD44v6. CD...

2026-08-20

Full-Life Technologies Completes Construction of Belgian Radiopharmaceutical Production Facility and Initiates Accelerator Commissioning

Full-Life Technologies (hereinafter referred to as "Full-Life"), a privately held, fully integrated, clinical-stage international radiopharmaceutical therapy company, announced on August 20 that its radiopharmaceutical production facility in Gembloux, Belgium, has completed construction and received authorization to commence accelerator commissioning and enter the initial ramp-up phase. (Full-Life Technologies Belgium Radiopharmaceutical Production Facility) This milestone marks a significant step forward in Full-Life's vertically integrated radioisotope production capabilities moving toward formal operational status. With the completion of facility construction, the company has entered the next phase of operational preparation, including accelerator installation, phased commissioning, and validation of critical safety and operational systems.

2026-08-20

Norway's Thor Medical AlphaOne High-Purity Alpha Radioisotope Facility to Be Officially Inaugurated

Thor Medical ASA announced on August 19 that its AlphaOne production facility at the Herøya industrial park in Norway will be officially inaugurated on September 9, 2026, with Norwegian Prime Minister Jonas Gahr Støre attending the ceremony. According to reports, AlphaOne is Thor Medical's first industrial-scale production facility for high-purity α radioisotopes and the first of its kind globally. The facility is already in operation, primarily producing isotope products for next-generation targeted cancer therapies, supplying high-purity α emitters to the radiopharmaceutical industry. Thor Medical CEO Jasper Kurth stated that AlphaOn...

2026-08-19

Dongcheng Pharmaceutical Adds New Radiopharmaceutical Production Center in Jinzhong, Shanxi

Recently, Shanxi Andike, a subsidiary of Dongcheng Andike, which is a wholly-owned subsidiary of Dongcheng Pharmaceutical, received the "Radiopharmaceutical Production License" issued by the Shanxi Provincial Drug Administration. This marks that the Jinzhong Radiopharmaceutical Production Center in Shanxi has met the requirements for commissioning, adding a new facility to Dongcheng Pharmaceutical's radiopharmaceutical production network. As one of China's leading nuclear medicine companies, the group adheres to a layout strategy of "networked short half-life and base-based long half-life" production, and has established a domestically leading radiopharmaceutical production and distribution network. To date, the group has put 33 radiopharmaceutical production centers into operation. As a heparin expert and radiopharmaceutical pioneer, Dongcheng Pharmaceutical will continue to deepen its presence in the nuclear medicine field, striving to build a comprehensive Dongcheng nuclear medicine ecosystem...

2026-08-18

Curium Acquires Belgium's Abscint, Expanding HER2-Targeted Gallium-68 PET Oncology Radiopharmaceutical Diagnostics Pipeline

On August 10, 2026, radiopharmaceutical company Curium announced the completion of its acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company. The transaction grants Curium global development, manufacturing, and commercialization rights to ABS-011, further expanding its oncology PET radiopharmaceutical diagnostics portfolio. ABS-011 is an investigational gallium-68-labeled positron emission tomography (PET) radiopharmaceutical diagnostic tracer targeting human epidermal growth factor receptor 2 (HER2). HER2 is an important biological target in multiple cancers, including breast cancer and gastric cancer. Based on available information, ABS-011 is designed to enable whole-body quantitative imaging of HER2 expression, and following further clinical development and regulatory approval, has the potential to provide more comprehensive HER2 status information for patient characterization and clinical assessment.

2026-08-11

Grand Pharma's FAP-targeted diagnostic radiopharmaceutical GPN01530-2 receives FDA Fast Track designation

On August 9, 2026, Grand Pharmaceutical issued a voluntary announcement stating that its self-developed global innovative radionuclide drug conjugate GPN01530-2 has recently been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of solid tumors. Previously, the product had already been approved by the FDA to conduct Phase I/II clinical studies for the diagnosis of solid tumors. GPN01530-2 is a small-molecule radionuclide drug conjugate (RDC) targeting fibroblast activation protein (FAP). Data shows that FAP is not expressed or is lowly expressed in normal tissues, but is highly expressed in tumor-associated fibroblasts within the tumor microenvironment of various cancers, and is considered a novel specific target in the field of tumor diagnosis and treatment...

2026-08-10

South Korea to Resume Actinium-225 Production Next Year to Ease Shortage of Raw Materials for Anti-Cancer Radiopharmaceuticals

South Korea's domestic production project for actinium-225 (Ac-225), a radioisotope used in next-generation cancer treatment, is expected to resume next year after being stalled for more than a year. Funding was secured in the first half of this year, and the Korea Institute of Radiological & Medical Sciences (KIRAMS) plans to complete facility construction and trial production before launching full-scale production in the second half of next year, aiming to alleviate the raw material shortage facing domestic clinical research and radiopharmaceutical development. KIRAMS is affiliated with the Ministry of Science and ICT. The institute received approval from the Nuclear Safety and Security Commission in May last year to produce Ac-225 using a cyclotron. The project first entered the review process in 2018 and took seven years to gain approval, with initial production originally planned by the end of last year. However, work on upgrading production facilities and procuring equipment was suspended after approximately 2 billion KRW in budget was not approved during parliamentary review.

2026-08-10

UAB startup LifeNuclear launches TheraGuide, a radiation safety guidance platform for radiopharmaceutical therapy

On August 7, LifeNuclear, a medical technology startup incubated by the University of Alabama at Birmingham (UAB), announced the launch of TheraGuide, a digital platform designed to help patients undergoing radiopharmaceutical cancer treatment understand and follow radiation safety guidance after discharge. Radiopharmaceutical therapy uses radioactive drugs to target cancer cells while minimizing damage to surrounding healthy tissue. As the therapy's applications expand, patients are typically required to read and follow complex written instructions after treatment, which can be difficult for some patients and caregivers to understand and execute. Dr. Remo George LifeNuclear was founded by UAB...

2026-08-08

China's First Homegrown Radiopharmaceutical Receives Dual FDA Breakthrough Therapy and Fast Track Designations

On August 6, Nuoyu Medical announced that the U.S. Food and Drug Administration (FDA) has officially granted Breakthrough Therapy Designation (BTD) and Fast Track Designation (FTD) to the company's independently developed 68Ga-NYM096. This marks the first product in China's original radiopharmaceutical field to receive FDA Breakthrough Therapy Designation, and the first to receive both FDA Breakthrough Therapy and Fast Track designations simultaneously, creating a milestone breakthrough in the radiopharmaceutical field. 68Ga-NYM096 is a small-molecule diagnostic radiopharmaceutical for renal cancer that specifically binds to CAIX, suitable for positron emission tomography (PET) imaging of suspected or confirmed metastatic clear cell renal cell carcinoma (c...

2026-08-08

Professor Lin Guoxian from the BC Cancer Agency Delivers Academic Exchange at the Institute of Radiation Medicine, Chinese Academy of Medical Sciences

Lin Guoxian: Professor at the BC Cancer Agency, whose research focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of various tumors. To date, he has led/participated in the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed the clinical translation of 7 self-developed radiopharmaceuticals for the diagnosis and treatment of multiple tumor types. During the seminar, Professor Lin Guoxian, based on his team's years of frontier exploration, systematically reviewed the research progress of nuclear drugs targeting PSMA for prostate cancer: first, the molecular design and clinical advantages of F-18 labeled PSMA-targeted PET imaging agents; second, the substantial improvement of tumor targeting of Lu-177 labeled therapeutic radiopharmaceuticals through rational optimization of molecular structures,...

2026-08-07

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Hosts Academic Seminar on PSMA-Targeted Radiopharmaceuticals

On August 3, the Institute of Radiation Medicine, Chinese Academy of Medical Sciences held an academic seminar, inviting Professor Lin Guoxian from the BC Cancer Agency in Vancouver, Canada, to deliver a lecture titled "Development of Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals for the Diagnosis and Treatment of Prostate Cancer." The seminar was held in a hybrid format, with some researchers and graduate students from the institute attending in person. Professor Lin Guoxian has long been engaged in the development of targeted radiopharmaceuticals for cancer diagnosis and therapy, having led or contributed to the publication of over 135 peer-reviewed journal articles, filed more than 30 patent applications related to radiopharmaceuticals, and completed clinical translation of 7 self-developed radiopharmaceuticals applied in...

2026-08-07

Indonesia's BRIN Showcases Nuclear Technology Research Progress, Covering Radiopharmaceuticals and Food Irradiation Applications

The National Research and Innovation Agency (BRIN) of Indonesia recently showcased its nuclear technology research achievements at the Presidential Palace in Jakarta. BRIN Head Arief Satria stated that the relevant technologies fall within the scope of peaceful uses of nuclear energy, with applications extending beyond energy to also cover food and health sectors. In the health sector, BRIN is developing radiopharmaceuticals for nuclear medicine. These drugs contain radioactive substances and can be used for cancer diagnosis and treatment. Arief stated that radiopharmaceutical research and development is of great significance for cancer detection and therapy. In the food sector, BRIN applies nuclear technology to food preservation, with a focus on irradiation treatment of export fruits. Arief explained that some importing countries re...

2026-08-07

South Korea Advances First Domestic Commercial Production of Lu-177 Using Wolsong Heavy Water Reactors

Korea Hydro & Nuclear Power (KHNP) plans to use the heavy water reactors at the Wolsong Nuclear Power Plant to produce, for the first time domestically, the radioisotope lutetium-177 (Lu-177) for cancer treatment. Currently, South Korea relies entirely on imports for this material, which imposes cost pressures and supply instability on local radiopharmaceutical companies such as Cellbion and FutureChem. Industry experts generally believe that domestic production will help build a diversified supply chain and shorten transportation times. The primary goal of this plan is to achieve commercial production of Lu-177, with pilot production expected in 2028 and full-scale production commencing in 2031. Subsequently, KHNP will expand production to include cobalt...

2026-08-06

Zhang Yiming, Chairman of HTA: Tackling the "Last Mile" of Nuclear Pharmacy Network Delivery to Bring Domestic Radiopharmaceuticals to Patients in Western and County-Level Regions

On July 28, the 2026 Radiopharmaceutical Innovation and Development Conference was held in Taiyuan, Shanxi Province. Zhang Yiming, Party Committee Secretary and Chairman of HTA, told reporters that the company is restructuring its short half-life radiopharmaceutical delivery system through "regional layout + standardized logistics + grassroots empowerment," striving to ensure that cancer patients in western and county-level regions can access domestically produced radiopharmaceuticals within the drug's effective half-life window. Currently, multi-dimensional policy dividends are being continuously released, and China's radiopharmaceutical industry is entering a critical window of opportunity. Alpha nuclide drugs represent the future direction of therapeutic radiopharmaceuticals. Zhang Yiming introduced that HTA has already made early arrangements for drug research in this field, jointly conducting research on actinium-225 labeled...

2026-08-05

BWXT to Sell Medical Business to Nordic Capital for Up to $800 Million

On August 3, BWX Technologies, Inc. announced that it has reached a definitive agreement to sell its medical business to healthcare investment company Nordic Capital. The transaction is valued at up to $800 million and includes BWXT Medical and the stable medical isotope business of Kinectrics. BWXT stated that the divestiture will help the company concentrate resources and capital to drive growth in its core nuclear national security business and commercial nuclear power market operations. The company believes these areas are its long-term strategic priorities. Under Nordic Capital's ownership, the medical business is expected to further expand its scale, enhance capabilities, and strengthen its position in the radiopharmaceutical field...

2026-08-04